Browse All

Current Filters

CLEAR FILTER x

TITLE

Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial

Author:Pittock, Sean   Barnett, Michael   Bennett, Jeffrey   Berthele, Achim   de Sèze, Jérôme   Levy, Michael   Nakashima, Ichiro   Oreja Guevara, Celia   Palace, Jacqueline   Paul, Friedemann   Pozzilli, Carlo   Allen, Kerstin   Mashhoon, Yasmin   Yountz, Marcus   Kim, Ho Jin   

Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

Topic:Autoimmune Neurology  

Program Number:S5.002  

Author Institution:Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA, Rochester, MN  Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia  Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia, Camperdown, Australia  Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado, Aurora, CO, USA, Aurora, CO  Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany, Muenchen, Germany  Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, Strasbourg, France, Strasbourg, France  Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA  Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan  Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Sendai, Japan  Department of Neurology, Hospital Clínico Universitario San Carlos, IdISCC, Madrid, Spain  Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain  Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK, Oxford, United Kingdom  Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany  Department of Human Neuroscience, University Sapienza, Rome, Italy, Rome, Italy  Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Boston, MA  Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Watertown, MA  Alexion, AstraZeneca Rare Disease, Boston, MA, USA *At the time this research was conducted., Needham, MA  Department of Neurology, National Cancer Center, Goyang, South Korea, Goyang, Korea, Republic of  

Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

Author:Levy, Michael   Pittock, Sean   Barnett, Michael   Bennett, Jeffrey   Berthele, Achim   De Seze, Jerome   Nakashima, Ichiro   Oreja Guevara, Celia   Palace, Jacqueline   Paul, Friedemann   Pozzilli, Carlo   Allen, Kerstin   Mashhoon, Yasmin   Yountz, Marcus   Kim, Ho Jin   

Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

Topic:Autoimmune Neurology  

Program Number:S5.003  

Author Institution:Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA  Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA, Rochester, MN  Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia  Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia, Camperdown, Australia  Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado, Aurora, CO, USA, Aurora, CO  Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany, Muenchen, Germany  Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, France, Strasbourg, France  Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan  Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Sendai, Japan  Department of Neurology, Hospital Clínico Universitario San Carlos, IdISCC, Madrid, Spain  Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain  Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK, Oxford, United Kingdom  Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany  Department of Human Neuroscience, University Sapienza, Rome, Italy, Rome, Italy  Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Boston, MA  Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Watertown, MA  Alexion, AstraZeneca Rare Disease, Boston, MA, USA *At the time this research was conducted., Needham, MA  Department of Neurology, National Cancer Center, Goyang, South Korea, Goyang, Korea, Republic of  

Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adults with Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder During the Phase 3 CHAMPION-NMOSD trial

Author:Ortiz, Stephan   Pittock, Sean   Berthele, Achim   Levy, Michael   Nakashima, Ichiro   Oreja Guevara, Celia   Kim, Ho Jin   

Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

Topic:Autoimmune Neurology  

Program Number:S5.004  

Author Institution:Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Boston, MA  Department of Neurology, Center MS and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA, Rochester, MN  Department of Neurology, School of Medicine, Technical University Munich, Munich, Germany, Munich, Germany  Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA  Department of Neurology, Tohoku University Graduate School of Medicine  Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Sendai, Japan  Department of Neurology, Hospital Clínico Universitario San Carlos  Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain  Department of Neurology, National Cancer Center, Goyang, South Korea , Goyang, Korea, Republic of  

Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis

Author:Cerqueira, Joao   Berthele, Achim   Cree, Bruce   Filippi, Massimo   Pardo, Gabriel   Pearson, Owen   Traboulsee, Anthony   Ziemssen, Tjalf   Vollmer, Timothy   Bernasconi, Corrado   Mandel, Corey   Kulyk, Inessa   Chognot, Cathy   Schneble, Hans-Martin   Prajapati, Kalpesh   Havrdova, Eva   

Session Name:S46: MS Therapeutics and Clinical Decision Making  

Topic:MS and Inflammatory Disease  

Program Number:S46.002  

Author Institution:2CA-Clinical Academic Centre Braga, Portugal Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga, Portugal, Lisbon, Portugal  School of Medicine, Technical University of Munich, Munich, Germany, Muenchen, Germany  University of California San Francisco, San Francisco, CA, USA, San Francisco, CA  IRCCS San Raffaele Scientific Institute, Milan, Italy, Milan, Italy  Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Oklahoma City, OK  Morriston Hospital, Swansea, UK, Swansea, United Kingdom  University of British Columbia, Vancouver, BC, Canada, Vancouver, BC, Canada  Dresden University of Technology, Dresden, Germany, Dresden, Germany  University of Colorado Denver, Denver, CO, USA, Aurora, CO  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Genentech, Inc., San Francisco, CA, USA, South San Francisco, CA  IQVIA Solutions, Inc., Amsterdam, The Netherlands, Amsterdam, Netherlands  General University Hospital and Charles University, Prague, Czech Republic, Praha 2, Czech Republic  

Real-world data on eculizumab treatment in NMOSD: high efficacy and potential challenges

Author:Ayzenberg, Ilya   Asseyer, Susanna   Lindenblatt, Gero   Fischer, Katinka   Pul, Refik   Özalp, Sinem-Hilal   Lohmann, Lisa   Giglhuber, Katrin   Häussler, Vivien   Karenfort, Michael   Hellwig, Kerstin   Paul, Friedemann   Bellmann-Strobl, Judith   Otto, Carolin   Ruprecht, Klemens   Ziemssen, Tjalf   Emmer, Alexander   Rothhammer, Veit   Nickel, Florian   Angstwurm, Klemens   Linker, Ralf   Warnke, Clemens   Jarius, Sven   Korporal-Kuhnke, Mirjam   Wildemann, Brigitte   Wolff, Stephanie   Seipelt, Maria   Yalachkov, Yavor   Retzlaff, Nele   Zettl, Uwe   Rommer, Paulus   Kowarik, Markus   Wickel, Jonathan   Geis, Christian   Hümmert, Martin W.   Trebst, Corinna   Senel, Makbule   Klotz, Luisa   Gold, Ralf   Kleinschnitz, Christoph   Meuth, Sven   Aktas, Orhan   Berthele, Achim   Ringelstein, Marius   

Session Name:P13: Autoimmune Neurology: NMOSD / MOGAD / Optic Neuritis  

Topic:Autoimmune Neurology  

Program Number:P13.017  

Author Institution:Ruhr-Universität Bochum, 44780 BOCHUM, Germany  Charite Universitätsmedizin in Berlin, Berlin, Germany  Department of Neurology, Johanna Etienne Hospital, Neuss, Germany  Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany  University Medicine Essen, University of Duisburg-Essen, Essen, Germany  University Hospital Münster, Munster, Germany  School of Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany  University Medical Center Hamburg-Eppendorf, Hamburg, Germany  Ruhr-Universität Bochum, Bochum, Germany  University Clinic Dresden, Dresden, Germany  University Hospital Halle, Halle, Germany  University Hospital Erlangen, Erlangen, Germany  University of Regensburg, Regensburg, Germany  University Hospital Köln, Koeln, Germany  University of Heidelberg, Heidelberg, Germany  University of Giessen, Giessen, Germany  University Hospital Marburg, Marburg, Germany  University Hospital Frankfurt, Frankfurt, Germany  University Hospital Rostock, Rostock, Germany  Medical University of Vienna, Vienna, Austria  University Hospital Tübingen, Tuebingen, Germany  Jena University Hospital, Jena, Germany  Hannover Medical School, Hannover, Germany  University Hospital Ulm, Ulm, Germany  University Hospital Münster, Münster, Germany  Medical Faculty, Heinrich-Heine-University Düsseldorf, Duesseldorf, Germany  School of Medicine, Technical University Munich, Klinikum rechts der Isar, Muenchen, Germany